Evidence map›Paper›PMID 29729390›Full record

ReviewNeuroImage2018

Advances in microstructural diffusion neuroimaging for psychiatric disorders.

Ofer Pasternak, Sinead Kelly, Valerie J Sydnor, Martha E Shenton

Abstract readReview
In one paragraph

Review in NeuroImage, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ofer PasternakDepartment of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ofer@bwh.harvard.edu.
Sinead KellyDepartment of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Public Psychiatry Division of the Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Valerie J SydnorDepartment of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Martha E ShentonDepartment of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Veteran Affairs Boston Healthcare System, Brockton Division, Brockton, MA, USA.

Funding

Training and DisseminationP41EB015902 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI WELLS, WILLIAM M. · 2012 to 2022
$20.9M
Novel DT-MRI Analyses of White Matter in SchizophreniaR01MH074794 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI WESTIN, CARL-FREDRIK · 2007 to 2021
$9.6M
Administrative Supplement Harmonization of At Risk Multisite Observational Networks for Youth(HARMONY)U01MH081928 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI STONE, WILLIAM SETH · 2008 to 2018
$7.1M
Neurodevelopment and Psychosis in the 22q11.2 Deletion SyndromeR01MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BEARDEN, CARRIE E · 2010 to 2020
$6.2M
Human Connectome Project for Early PsychosisU01MH109977 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI BREIER, ALAN, SHENTON, MARTHA E. · 2016 to 2020
$5.5M
Identifying mechanisms of response to therapeutic intervention in clinical high risk (CHR) for psychosis: a bridge to treatmentR01MH111448 · NIMH · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LI, HUIJUN, NIZNIKIEWICZ, MARGARET A · 2016 to 2023
$4.4M
Neurodevelopment and Psychosis in the 22q11.2 Copy Number VariantsR37MH085953 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CARRIE E BEARDEN · 2023 to 2026
$2.9M
Diffusion Imaging Biomarkers for Risk, Onset and Outcome in SchizophreniaR01MH102377 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI KUBICKI, MAREK · 2014 to 2018
$2.8M
Next Generation Diffusion MRI Biomarkers for Prodromal SchizophreniaR01MH108574 · NIMH · BRIGHAM AND WOMEN'S HOSPITAL · PI PASTERNAK, OFER · 2016 to 2020
$2.2M
MR Brain Diffusion Tensor Imaging in SchizophreniaI01CX000176 · VA · VA BOSTON HEALTH CARE SYSTEM · PI SHENTON, MARTHA E. · 2009 to 2019
–
CSRD VA I01 CX000176NIBIB NIH HHS P41 EB015902NIH HHS P41EB015902NIH HHS R01MH074794NIH HHS R01MH085953NIH HHS R01MH102377NIH HHS R01MH108574NIH HHS R01MH111448NIH HHS U01MH081928NIH HHS U01MH109977NIMH NIH HHS R01 MH074794NIMH NIH HHS R01 MH085953NIMH NIH HHS R01 MH102377NIMH NIH HHS R01 MH108574NIMH NIH HHS R01 MH111448NIMH NIH HHS R37 MH085953NIMH NIH HHS U01 MH081928NIMH NIH HHS U01 MH109977
6 · The paper itself

Abstract

Understanding the neuropathological underpinnings of mental disorders such as schizophrenia, major depression, and bipolar disorder is an essential step towards the development of targeted treatments. Diffusion MRI studies utilizing the diffusion tensor imaging (DTI) model have been extremely successful to date in identifying microstructural brain abnormalities in individuals suffering from mental illness, especially in regions of white matter, although identified abnormalities have been biologically non-specific. Building on DTI's success, in recent years more advanced diffusion MRI methods have been developed and applied to the study of psychiatric populations, with the aim of offering increased sensitivity to subtle neurological abnormalities, as well as improved specificity to candidate pathologies such as demyelination and neuroinflammation. These advanced methods, however, usually come at the cost of prolonged imaging sequences or reduced signal to noise, and they are more difficult to evaluate compared with the more simplified approach taken by the now common DTI model. To date, a limited number of advanced diffusion MRI methods have been employed to study schizophrenia, major depression and bipolar disorder populations. In this review we survey these studies, compare findings across diverse methods, discuss the main benefits and limitations of the different methods, and assess the extent to which the application of more advanced diffusion imaging approaches has led to novel and transformative information with regards to our ability to better understand the etiology and pathology of mental disorders.

Indexed as

Bipolar DisorderDiffusion Magnetic Resonance ImagingHumansMajor Depressive DisorderNeuroimagingSchizophreniaBipolar disorderDiffusion MRIMajor depressionMicrostructureSchizophrenia

Identifiers

PMID29729390
PMCPMC6420686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.